Business Trends– category –
-
Sana Biotechnology to Initiate Hypoimmune Cell Therapy and In Vivo CAR T Trials This Year, with Data Expected Within 12 Months
TradingView USA Overview Sana Biotechnology is set to commence clinical trials for two key platforms this year: a hypoimmune cell therapy targeting Type 1 diabetes and an in vivo CAR T platform for oncology and autoimmune diseases. Initi... -
Made Scientific and Pluristyx Announce Integrated iPSC Development & Manufacturing Partnership to Accelerate Next-Generation iPSC-Derived Cell Therapies
PR Newswire USA Overview Made Scientific, a cell therapy CDMO, and Pluristyx, an iPSC platform technology provider, announced an integrated iPSC development and manufacturing partnership. This collaboration aims to accelerate the clinica... -
Century Therapeutics to Present iPSC-Derived CNTY-813 (Featuring Allo-Evasion™ 5.0) for Type 1 Diabetes at ADA 86th Scientific Sessions
Benzinga USA Overview Century Therapeutics is scheduled to deliver an oral presentation on its innovative iPSC-derived islet cell replacement therapy, CNTY-813, for Type 1 diabetes at the American Diabetes Association (ADA) 86th Scientif... -
Beam Therapeutics Stock Rises 2.04% After Receiving Triangle Business Journal’s 2026 Life Sciences Award, Signaling Heightened Market Optimism
Traders Union USA Overview Beam Therapeutics received the prestigious 2026 Life Sciences Award from Triangle Business Journal, acknowledging its innovative contributions. Concurrently, the company's stock experienced a 2.04% rise, reflec... -
Intellia Therapeutics to Unveil Additional Phase 3 HAELO Data for Lonvo-z, a Hereditary Angioedema Therapy, at EAACI Annual Congress
Quiver Quantitative USA Overview Intellia Therapeutics announced it would present additional Phase 3 HAELO clinical trial data for lonvo-z (lonvoguran ziclumeran), its CRISPR-based gene-editing therapy for hereditary angioedema (HAE), at... -
CRISPR Therapeutics to Detail Broadening Gene-Editing Pipeline at June Investor Conferences, Highlighting Approved Casgevy and Multidisease Programs
Market Chameleon USA Overview CRISPR Therapeutics announced plans to present its expanding gene-editing pipeline at three major investor conferences in early June 2026. The company will discuss the commercial progress of its approved gen... -
Loop Industries Confronts ‘Going Concern’ Risk Amid Global Commercialization of Infinite Loop™ PET Recycling Technology
stocktitan.net USA Overview Loop Industries is advancing the global commercialization of its Infinite Loop™ technology, a low-temperature depolymerization process that transforms waste PET plastic and polyester fiber into virgin-quality ... -
Technip Energies and Agilyx Launch TruStyrenyx™ for High-Purity Recycled Styrene Monomer Production
Ingenious-e-Brain Global Overview Technip Energies and Agilyx have introduced TruStyrenyx™, an integrated solution for the chemical recycling of polystyrene, combining Agilyx's pyrolysis process with Technip Energies' purification techno... -
Valmet Pioneers High-Speed Pyrolysis for Transformative Plastic Chemical Recycling
Valmet フィンランド Overview Valmet, a Finnish technology leader, has unveiled an advanced chemical recycling solution utilizing high-speed pyrolysis to convert challenging mixed plastic waste—including PE, PP, and PS—into virgin-quality... -
German Quantum Firm QUDORA Establishes Japan Subsidiary to Expand Asia-Pacific Quantum Computing Market with Microwave NFQC Technology
QUDORA (via Quantum Zeitgeist) Germany Overview German quantum computing firm QUDORA has launched Qudora Japan K.K. in Tokyo to expand its commercial footprint in the Asia-Pacific region. QUDORA leverages its unique microwave Near-Field ...
